Shares of Navin Fluorine International, one of the largest Indian manufacturers of speciality fluorochemicals, surged 17.3% in Friday’s intraday trade, October 31, to hit a fresh record high of ₹5,839 ...

To expedite the hospital construction works, Revanth Reddy announced the constitution of a coordination committee with the officials and engineers of medical and health, police, GHMC, roads and ...

Navin Fluorine International Ltd shares surged to a record high buoyed by strong quarterly earnings and fresh capital expenditure announcements. Investor sentiment turned positive after the company ...

Discover whether n8n or Python is the best tool for your AI projects. Explore their strengths, limitations, and how to make the right choice.

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Friday reported earnings of $162 million in its fiscal second quarter. On a per-share basis, the Hyderabad, India ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update from Dr Reddy’s Laboratories ( ...

Dr Reddy's Laboratories on October 24 reported a 7 percent year-on-year rise in net profit to Rs 1,347.1 crore in Q2 FY26. This is lower than the Rs 1,450 crore net profit estimated by brokerages ...

Shares of Dr. Reddy's Laboratories Ltd. 500124 rose 1.29% to 1,256.00 Indian rupees Friday, on what proved to be an all-around positive trading session for the stock market, with the BSE SENSEX Index ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.32% to 1,284.00 Indian rupees Friday, on what proved to be an all-around rough trading session for the stock market, with the BSE SENSEX Index 1 ...

Dr. Reddy's Laboratories reported consolidated revenues of ₹8,805 crore in Q2FY26, up 9.8% year-on-year and 3% sequentially. Profit after tax rose 14% to ₹1,437 crore, while EBITDA stood at ₹2,351 ...

Dr Reddy’s Laboratories’ stock fell as much as 1 percent on Monday, October 27, after the drugmaker reported July-September quarter earnings that came in below expectations due to weak performance in ...